Author: Ravi Shankar

BAYONNE, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) — BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), announced today that the Bank has entered into definitive agreements to sell several portfolios of certain problem loans, most of which are rated criticized or classified under the Bank’s internal risk rating system. Between September 21 and September 24, 2026, the Bank entered into definitive agreements with six different purchasers providing for the sale of loans with an aggregate unpaid principal balance of approximately $205.3 million as of June 30, 2026.

The portfolios being sold consist of commercial and multifamily real estate loans with an aggregate unpaid principal balance of approximately $180.7 million, commercial and industrial (C&I) loans with an aggregate unpaid principal balance of approximately $14.8 million, and construction loans with an aggregate unpaid principal balance of approximately $9.8 million, in each case, as of June 30, 2026. None of the Bank’s business express loans are included in the portfolios. The estimated pre-tax loss attributable to these loan sales is $43.3 million, which will be recorded in the third quarter of 2026.

Closing has occurred with respect to five of the six loan sale transactions, with the last transaction expected to close before the end of the third quarter of 2026. Each definitive agreement is independent of the others, and the closing of any one agreement was not conditioned on the closing of any other.

Hilltop Securities Inc. served as financial advisor and Arnold & Porter Kaye Scholer LLP served as legal counsel to the Bank in connection with the successful execution of these transactions.

Thomas M. O’Brien, President and Chief Executive Officer of the Company and the Bank, stated, “Since I joined the Company, we have moved quickly to reassess our credit risk ratings and take decisive action on our legacy credit challenges. We committed to aggressively address these issues and to put transparent, actionable solutions in place promptly, and the sale transactions we are announcing today, covering approximately $205 million in problem loans, reflect that commitment in practice. We believe these sales meaningfully de-risk our balance sheet and remove a significant source of uncertainty, allowing us to focus our energy on building a stronger, more sustainable, and profitable institution going forward.”

About BCB Bancorp, Inc.

Established in 2000 and headquartered in Bayonne, N.J., BCB Community Bank is the wholly-owned subsidiary of BCB Bancorp, Inc. (NASDAQ: BCBP). The Bank has twenty-two branch offices in Bayonne, Edison, Hoboken, Fairfield, Holmdel, Jersey City, Lyndhurst, Maplewood, Monroe Township, Newark, Plainsboro, River Edge, Rutherford, South Orange, Union, and Woodbridge, New Jersey, and four branches in Hicksville and Staten Island, New York. The Bank provides businesses and individuals a wide range of loans, deposit products, and retail and commercial banking services. For more information, please go to www.bcb.bank.

Forward-Looking Statements

This release, like many written and oral communications presented by BCB Bancorp, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results.

The most significant factors that could cause future results to differ materially from those anticipated by our forward-looking statements include the global impact of the military conflicts in the Ukraine and the Middle East, the potential impact of any future Federal budget stalemate in Congress, global tariffs imposed by the Trump administration, higher inflation levels, and general economic concerns, all of which could impact economic growth and could cause increased loan delinquencies, a reduction in financial transactions and business activities, including decreased deposits and reduced loan originations. Other factors that could cause future results to vary materially from current management expectations as reflected in our forward-looking statements include, but are not limited to: our ability to manage liquidity and capital in a rapidly changing and unpredictable market, supply chain disruptions, labor shortages; unfavorable economic conditions in the United States generally and particularly in our primary market area; the Company’s ability to effectively attract and deploy deposits; changes in the Company’s corporate strategies, the composition of its assets, or the way in which it funds those assets; shifts in investor sentiment or behavior in the securities, capital, or other financial markets, including changes in market liquidity or volatility; the effects of declines in real estate values that may adversely impact the collateral underlying our loans; increase in unemployment levels and slowdowns in economic growth; our level of non-performing assets and the costs associated with resolving any problem loans including litigation and other costs; the impact of changes in interest rates and the credit quality and strength of underlying collateral and the effect of such changes on the market value of our loan and investment securities portfolios; the credit risk associated with our loan portfolio; changes in the quality and composition of the Bank’s loan and investment portfolios; changes in our ability to access cost-effective funding; deposit flows; legislative and regulatory changes, including increases in Federal Deposit Insurance Corporation, or FDIC, insurance rates; monetary and fiscal policies of the federal and state governments; changes in tax policies, rates and regulations of federal, state and local tax authorities; demands for our loan products; demand for financial services; competition; changes in the securities or secondary mortgage markets; changes in management’s business strategies; changes in consumer spending; our ability to hire and retain key employees; the effects of any reputational, credit, interest rate, market, operational, legal, liquidity, or regulatory risk; expanding regulatory requirements which could adversely affect operating results; civil unrest in the communities that we serve; and other factors discussed elsewhere in this report, and in other reports we filed with the SEC, including under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K filed for the year ended December 31, 2025, and our other periodic reports that we file with the SEC.

CONTACT:	JAWAD CHAUDHRY,
	EVP, CFO & TREASURER
	(800) 680-6872

CALGARY, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) (TSX: CMG), today announced that it has taken up and paid for 4,444,444 of its common shares (“Shares”) at a price of C$4.50 per Share (the “Purchase Price”) under CMG’s substantial issuer bid (the “SIB”) to repurchase for cancellation a number of its Shares for an aggregate purchase price not to exceed C$20 million.

Final Results of SIB

The Shares purchased under the SIB represent an aggregate purchase price of approximately C$19,999,998 and approximately 5.7% of the total number of CMG’s issued and outstanding Shares as of September 21, 2026. After giving effect to the SIB, CMG will have approximately 73.6 million Shares issued and outstanding.

Based on the final calculations of Olympia Trust Company (the “Depositary”) as depositary for the SIB, a total of 4,657,844 Shares were tendered to the SIB pursuant to auction tenders and purchase price tenders, of which 3,933,679 Shares were taken up and purchased. Since the SIB was oversubscribed, shareholders who made auction tenders at or below the Purchase Price and shareholders who made, or were deemed to have made, purchase price tenders had approximately 84% of their successfully tendered Shares purchased by CMG (other than “odd lot” tenders, which were not subject to proration). In addition, 8,966,715 Shares were tendered pursuant to proportionate tenders, of which 510,765 Shares were taken up and purchased.

Payment and settlement of the purchased Shares will be effected by the Depositary on or about September 30, 2026 in accordance with the SIB and applicable law. Any Shares not purchased, including Shares invalidly tendered, will be returned to shareholders promptly by the Depositary.

The full details of the SIB are described in the offer to purchase and issuer bid circular dated August 14, 2026, as well as the related letter of transmittal and notice of guaranteed delivery, copies of which were filed and are available under our profile on SEDAR+ at www.sedarplus.ca.

To assist shareholders in determining the tax consequences of the SIB, CMG estimates that for the purposes of the Income Tax Act (Canada), the paid-up capital per Share is approximately C$1.025. Given that the Purchase Price exceeds the paid-up capital per Share, shareholders who have sold Shares to CMG under the SIB will be deemed to have received a taxable dividend as a result of such sale for Canadian federal income tax purposes equal to the amount by which the Purchase Price exceeds the paid-up capital per Share. The dividend deemed to have been paid by CMG to Canadian resident persons is designated as an “eligible dividend” for purposes of the Income Tax Act (Canada) and any corresponding provincial and territorial tax legislation.

The “specified amount” for purposes of subsection 191(4) of the Income Tax Act (Canada) is C$3.89, being the closing trading price for the Shares on the TSX on September 21, 2026.

Shareholders should consult with their own tax and other advisors with respect to the income tax consequences of the disposition of their Shares under the SIB.

This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Shares.

Forward-Looking Information

Certain information in this press release may constitute “forward-looking information” within the meaning of applicable securities legislation. All information contained in this press release, other than statements of current and historical fact, is forward-looking information, including statements regarding the terms of the SIB (including the timing of payment and settlement of Shares purchased under the SIB), the number of Shares expected to be issued and outstanding after completion of the SIB, and other statements that are not historical facts (collectively, “forward-looking information”). Generally, forward-looking information can be identified by use of words such as “may”, “will”, “expect”, “believe”, “anticipate”, “estimate”, “intend”, “plan”, “would”, “could”, “should”, “continue”, “goal”, “objective”, “remain” and other similar terminology.

Forward-looking information is not, and cannot be, a guarantee of future results or events. Forward-looking information is necessarily based on a number of opinions, estimates, and assumptions that the Company considered appropriate and reasonable as of the date such statements are made. Although the forward-looking information contained herein is based upon what the Company believes are reasonable assumptions, actual results may vary from the forward-looking information contained herein. Certain assumptions made in preparing the forward-looking information contained herein include, without limitation, that all reported tenders were validly made and the absence of changes to applicable laws, regulations or policies affecting issuer bids. Inherent in the forward-looking information are known and unknown risks, uncertainties and other factors that could cause actual results or performance to differ materially from any results or performance expressed or implied by such forward-looking information. Details of these risks are described in the Company’s annual publicly filed documents, including the Annual Information Form for the year ended March 31, 2026 (which are available on the Company’s profile on SEDAR+ at www.sedarplus.ca).

Investors should not place undue reliance on forward-looking information as a prediction of actual results. The forward-looking information reflects management’s current expectations and beliefs regarding future events and performance and is based on information currently available to management. Although we have attempted to identify important factors that could cause actual results to differ materially from the forward-looking information contained herein, there are other factors that could cause results not to be as anticipated, estimated or intended. The forward-looking information contained herein is current as of the date of this press release and, except as required under applicable law, we do not undertake to update or revise it to reflect new events or circumstances.

About CMG

CMG (TSX: CMG) is a global software and consulting company that combines science and technology with deep industry expertise to solve complex subsurface and surface challenges for the energy industry around the world. CMG is headquartered in Calgary, AB, with offices globally. For more information, visit www.cmgl.ca.

CONTACT: For investor inquiries, please contact:

Kim MacEachern
Director, Investor Relations
cmg-investors@cmgl.ca

For media inquiries, please contact: marketing@cmgl.ca

ATHENS, Greece, Sept. 25, 2026 (GLOBE NEWSWIRE) — Rubico Inc. (Nasdaq: RUBI) (“Rubico,” or the “Company”), a global provider of shipping transportation services specializing in the ownership of vessels, announces that, in relation to the previously announced stock dividend of 0.50 common shares for each common share outstanding (the “Stock Dividend”), the Nasdaq Capital Market (“Nasdaq”) has determined that the ex-dividend date will be October 6, 2026. The Stock Dividend will be distributed on or about October 5, 2026 (the “Distribution Date”) to shareholders of record as of the close of business on September 28, 2026. No fractional shares will be issued in connection with the Stock Dividend; any fractional shares resulting from the Stock Dividend will be paid in cash based on the closing price of the Company’s common shares on Nasdaq on September 28, 2026.

As a result of “due bill” trading procedures expected to be established by Nasdaq, Rubico common shares are expected to trade with due bills from September 28, 2026 through and including the Distribution Date. Accordingly, holders of Rubico common shares as of September 28, 2026 will need to hold such shares through and including the Distribution Date in order to receive the Stock Dividend.

This would mean that holders who purchase Rubico common shares during the due bill period (even if the trades are to be settled after the due bill period) will be entitled to receive the Stock Dividend with respect to those shares. Conversely, sellers who sell Rubico common shares during the due bill period (even if the trades are to be settled after the due bill period) will not be entitled to the Stock Dividend with respect to those shares.

Due bills obligate a seller of securities to deliver the distribution payable on such securities to the buyer. The due bill obligations are customarily settled between the brokers representing buyers and sellers of the securities. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of Rubico’s common shares should consult their brokers before trading to ensure they understand the effect of Nasdaq’s due bill procedures.

About the Company

Rubico Inc. is a global provider of shipping transportation services specializing in the ownership of vessels. The Company is an international owner and operator of two modern, fuel efficient, eco 157,000 dwt Suezmax tankers. Furthermore, the Company owns two 47,499 dwt MR tanker newbuildings scheduled for delivery in the third and fourth quarters of 2029 and a 60-meter newbuilding megayacht scheduled for delivery in the second quarter of 2027, which the Company intends to divest. In addition, the Company has entered into a share purchase agreement to acquire a shipowning company that owns one high-specification 47,499 dwt MR tanker newbuilding scheduled for delivery in the second quarter of 2029, with closing of this share purchase agreement to occur by September 30, 2026.

The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Athens, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “RUBI”.

Please visit the Company’s website at: https://rubicoinc.com/

For further information please contact:

Nikolaos Papastratis
Chief Financial Officer
Rubico Inc.
Tel: +30 210 812 8107
Email: npapastratis@rubicoinc.com

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including statements regarding the distribution of the Stock Dividend, the payment of cash in lieu of fractional shares and Nasdaq trading procedures.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. Please see the Company’s filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

PASCAGOULA, Miss., Sept. 25, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) welcomed members of the National Commission on the Future of the Navy (FNC) to its Ingalls Shipbuilding division Thursday as part of the commission’s nationwide review to develop recommendations for strengthening American seapower.

The visit provided commission members with a firsthand look at the shipbuilding capabilities, workforce training and industrial investments that support the Navy’s future fleet requirements. As part of its comprehensive study of naval strategy, resources, force structure and the industrial base, the commission is assessing the nation’s shipbuilding capacity and long-term production needs.

“A strong Navy relies on a capable and resilient industrial base,” Commissioner Mitch Waldman said. “We are grateful for the opportunity to see firsthand the significant industrial capacity and workforce capability that Ingalls Shipbuilding provides as the commission continues to assess the nation’s ability to design, build and sustain the future Navy.”

During the visit, commission members toured key production and training areas, including the Flight III Arleigh Burke-class destroyer Jeremiah Denton (DDG 129), the Virtual Reality Welding Lab and the Maritime Training Academy. The tour highlighted the pace and scale of Ingalls’ operations, as well as major infrastructure investments designed to support increased throughput across the U.S. maritime industrial base.

A photo accompanying this release is available at: http://hii.com/news/hii-hosts-national-commission-on-the-future-of-the-navy-at-ingalls-shipbuilding/.

“Ingalls shipbuilders bring unmatched skill and dedication to every ship we build, and it was a privilege to show the commission how their work in the shipyard directly supports the fleet,” said Eric Crooker, Ingalls vice president of program management. “With more than 87 years of experience building ships for the U.S. Navy, and over a dozen ships in active construction, our team’s dedication and upcoming ship deliveries demonstrate the strength of our workforce and the capability we provide to the nation.”

With 13 ships in construction and three deliveries planned in the next year, Ingalls Shipbuilding offers a firsthand view of the production capacity and workforce capabilities central to meeting future fleet requirements. The shipyard’s recent progress through its distributed shipbuilding program further illustrates its role in the broader maritime industrial base.

Congress established the FNC to provide an independent review of naval force structure, shipbuilding performance and industrial-base requirements. Public hearings began in March 2026, with initial findings expected in January 2027.

As America’s largest shipbuilder, HII supports national defense by building and maintaining the Navy and Marine Corps ships that underpin U.S. seapower. Through investments in advanced digital and automated production technologies, workforce development and industrial-base capacity, HII works to support the readiness and sustainment of the nation’s fleet.

For more information about HII’s Ingalls Shipbuilding division, visit hii.com/ingalls-shipbuilding.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:
Kimberly K. Aguillard
Kimberly.K.Aguillard@hii-co.com
228-355-5663

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a96e7c21-b940-4853-a8f2-67affed0db53

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Attachment

• 20260925 SBB EN

 PRESS RELEASE
Nantes, September 25th, 2026

H1 2026 Results: Continued cost discipline and balance sheet  restoration amidst a persistently challenging top-line environment 

Reminder: since July 2026, the Group has been operating with a strengthened balance sheet following the refinancing agreement reached with its main stakeholders. Full details are available in the press release dated July 31, 2026. 

Net sales reached €412.8m, down 7.1% vs LY (-5.8% LfL) in a subdued market

 €15m gross savings achieved

Working Capital improvement

• Net Sales reached €412.8m, down 7.1% YoY (-5.8% on a LfL basis):
  • Performance contracted further in Q2 (-9.8%) compared to Q1 (-4.5%), impacted by constrained inventory levels and a deliberate scale-back of promotional activities 
  • The store network keeps proving resilience at -3.0% LfL. Southern Europe remained almost flat (-1.0% LfL), while France declined by -4.0% LfL, in line with market trends (IPEA) while Online experienced a steeper decline (-11.8%)

• Profitability & Cost Savings:
  • Current EBIT stood at -€36.8m (vs. -€22.0m in H1 2025).
  • Gross Margin to 61.9% reflects promotional support in Q1 
  • €15m gross cost savings achieved partially offset lower volumes, driven by major efforts in logistics and transportation

• Cash Flow & Balance Sheet:
  • Free Cash Flow improved to -€49.8m (vs. -€64.9m in H1 2025), reflecting EBIT contraction offset by net working capital improvement driven by lower inventory 

François-Melchior de Polignac, CEO of Maisons du Monde, commented: “In the first half of 2026, we operated in a challenging market environment while managing constrained inventory levels. Faced with these headwinds, we remained intensely focused on our priorities: cost reduction, cash preservation, and maintaining customer satisfaction.

Following the refinancing completed in July, we now operate with a lighter and secured balance sheet. With the backing of our new majority shareholders, we have the financial stability and operational support required to execute our turnaround and build a profitable, sustainable model for the long term.” 

H1 2026 Sales

	H1 26	H1 25	%
€ in millions	Actual	Actual	Variation
Group GMV	483,3	513,1	(5,8%)
Net sales	412,8	444,6	(7,1%)
Like-for-like sales	404,0	428,9	(5,8%)
Sales by geography
France	223,4	239,3	(6,6%)
% of sales	54,1%	53,8%	0,3ppt
International	189,4	205,3	(7,8%)
% of sales	45,9%	46,2%	(0,3ppt)
Sales by distribution channel
Stores	302,4	319,4	(5,3%)
% of sales	73,2%	71,8%	1,4ppt
Online	110,4	125,2	(11,8%)
% of sales	26,8%	28,2%	(1,4ppt)
Sales by product category
Decoration	210,6	232,2	(9,3%)
% of sales	51,0%	52,2%	(1,2ppt)
Furniture	202,2	212,4	(4,8%)
% of sales	49,0%	47,8%	1,2ppt

Group sales for the first half of 2026 reached €412.8 million, down 7.1% overall and -5.8% at constant scope compared to H1 2025.

International sales declined at a faster pace, reflecting contrasted performances across regions, with resilient activity in Southern Europe offset by stronger pressure in Germany and Austria.

The Group continued the proactive management of its store network in line with its transformation plan. As of June 30, 2026, the store network stood at 326 stores, including 22 affiliates.

H1 2026 financial performance 

EBIT

	H1 26	H1 25	%
€ in millions	Actual	Actual	Variation
Net sales	412,8	444,6	(7,1%)
Cost of Goods Sold (1)	(157,2)	(158,5)	(0,8%)
Gross Margin	255,5	286,1	(10,7%)
As a % of net Sales	61,9%	64,3%	(2,4ppt)
Stores and central costs	(159,3)	(159,3)	(0,0%)
Logistic costs	(69,1)	(80,8)	(14,5%)
Operating costs	(228,4)	(240,1)	(4,8%)
Current EBITDA	27,1	46,0	(41,0%)
As a % of net Sales	6,6%	10,3%	(3,7ppt)
D&A	(64,0)	(68,0)	(5,9%)
As a % of net Sales	(15,5%)	(15,3%)	(0,2ppt)
Current EBIT	(36,8)	(22,0)	n.a
As a % of net Sales	(8,9%)	(4,9%)	(4,0ppt)

(1) The difference in amount with the cost of sales in the consolidated income statements corresponds to the net operating expenses of the factory and the container traction company.

Gross margin rate decreased by 240 basis points to 61.9% compared to H1 2025. This contraction was primarily driven by higher promotional activity in Q1 and a challenging comparison base due to a non-recurring favorable item in H1 2025. During Q2, we took the deliberate decision to reduce promotional intensity. 

Operating costs totaled €228 million, down 4.8% year-on-year. This reduction reflects the tangible benefits of the €15 million gross cost-saving plan (which also impacted the cost of goods sold). These gains were partially offset by temporary inflationary pressures, notably on fuel, and transformation costs linked to ongoing IT investments.

Current EBITDA stood at €27 million, down from €46 million in H1 2025.

D&A decreased slightly, reflecting gradual Capex diminution and was also driven by the closure of 2 stores during the half-year.

Current EBIT stood at -€37 million (vs. -€22 million in H1 2025), reflecting top-line pressure and gross margin compression. 

NET RESULT

€ in millions	H1 26	H1 25
Current EBIT	(36,8)	(22,0)
Financial results	(14,8)	(11,3)
Other operating income & expenses	(10,1)	(49,1)
Other income & expenses	(0,8)	(1,2)
Fair value financial instruments	(0,6)	(1,0)
Income tax	(0,9)	9,0
Net income	(64,0)	(75,6)

Net loss for the period stood at -€64.0 million, compared to -€75.6 million in H1 2025. Main drivers included:

• €10.1 million in other operating expenses, covering store closure costs and restructuring expenses.
• A net financial result of -€14.8 million, showing an increased charge compared to H1 2025 due to a higher cost of debt.
• An income tax expense close to nil.

FREE CASH FLOW

(in EUR million)		H1 2026	H1 2025
Current EBITDA		27.1	46.0
Change in working capital		7.7	(41.0)
Change in other operating items		(7.0)	(3.3)
Net cash generated by/ (used in) operating activities		27.8	1.7
Capital expenditures (Capex)		(23.2)	(9.4)
Change in debt on fixed assets		2.4	(0.7)
Proceeds from sale of non-current assets		–	1.3
Interest received		0.2	–
Decrease in lease debt		(50.6)	(51.3)
Lease interest paid		(6.4)	(6.5)
Free cash flow		(49.8)	(64.9)

Free Cash Flow stood at -€49.8 million for H1 2026, improving from -€64.9 million in H1 2025.

• Capital Expenditure (Capex) reached €23.2 million, which includes a €10 million cash deposit required to secure operations during ongoing refinancing processes. Excluding this deposit, core investments amounted to €13.2 million, primarily allocated to IT tools and store network improvements.
• Net working capital improved, driven by strong inventory control, reducing stock levels from €181.8 million as of December 31, 2025, to €160.5 million as of June 30, 2026.

NET FINANCIAL DEBT

(€ in millions)		30 June 2026 Pro forma (1)	30 June 2026	31 December 2025
Term loan		41.0	51.3	50.4
Revolving Credit Facilities (RCF)		25.0	199.5	195.8
Other debt		0.9	7.2	7.3
Gross debt		66.9	258.0	253.5
Finance leases		427.2	427.2	473.9
Cash & Cash equivalents		(42.4)	(42.4)	(96.1)
Net debt (IFRS 16)		451.7	642.8	631.3
Less : lease debt (IFRS 16)		(427.2)	(427.2)	(473.9)
Plus : lease debt (finance lease)		0.1	0.1	0.3
Net debt (without IFRS 16)		24.6	215.7	157.7

1. Unaudited, as if the refinancing had been completed at 30 June 2026

In July 2026, the Group successfully reached an agreement with its key stakeholders, including the French State, Banking partners, and Investors to execute a comprehensive debt refinancing. On a restated basis, this agreement significantly de-leverages the Group, bringing Net Financial Debt down to €24.6 million as of June 30, 2026, and restoring a healthy balance sheet structure. 

The guarantees related to the New Financing provided by the Consortium and the Participating Banks are currently being put in place. As a reminder, these guarantees consist of:

• A security and management trust (fiducie sûreté et gestion) or a pledge over the Group’s strategic assets (including 100% of the shares in Maisons du Monde France held by the Company and 100% of the shares in the Group’s main operating subsidiaries, all intellectual property rights of Maisons du Monde France (including the trademark), all merchandise inventory belonging to Maisons du Monde France, intercompany receivables held by the Company and Maisons du Monde France, and the bank accounts of the Company and Maisons du Monde France);
• A joint and several guarantee from the Company covering all obligations of Maisons du Monde France under the new financing.

In this transition context, the Group is not providing financial guidance.

OTHERS

The Company’s Board of Directors consists of seven members, including three independent directors (John Browett, Cécile Cloarec, and Laure Hauseux, the latter possessing specific financial and accounting expertise). The other directors, in addition to Alteri Investors and Eicos Investment Group, are François-Melchior de Polignac (Chief Executive Officer) and Stéphane Boussard (employee representative director). 

Regarding its corporate governance code, Maisons du Monde previously applied the AFEP-MEDEF Code. At its meeting on September 25, the Board of Directors decided that the Group will now adhere to the MiddleNext “Corporate Governance Code for Small and Mid-Caps”. The Board considers this code more suited to the company’s size and specific characteristics, notably given the presence of a reference shareholder now holding nearly 95% of the Company’s share capital as well as the reduction of the number of Board members.

The Board of Directors meeting on 25 September also decided that the Board of Directors would from now on perform the duties assigned to the audit committee, pursuant to Article L. 821-68 4° of the French Commercial Code. 

The statutory auditors expect to issue an unqualified limited review report on the Group’s condensed interim consolidated financial statements as of June 30, 2026, including an emphasis-of-matter paragraph regarding the uncertainty related to the Group’s ability to continue as a going concern.

Consolidated income statement

		H1 2026		H1 2025
(in EUR million)
Retail sales and commissions related to ordinary activities		412.8		444.6
Other revenue		10.3		12.2
Total revenue		423.2		456.8
Cost of sales		(152.4)		(152.7)
Personnel expenses		(100.4)		(105.2)
External expenses		(144.7)		(155.5)
Depreciation, amortisation and allowance for provisions		(63.9)		(68.0)
Fair value – derivative financial instruments		(0.6)		(1.0)
Other income/(expenses) from operations		0.6		1.3
Current operating profit		(38.2)		(24.3)
Other operating income and expenses		(10.1)		(49.1)
Operating profit / (loss)		(48.3)		(73.3)
Cost of net debt		(8.5)		(5.7)
Cost of lease debt		(6.3)		(6.6)
Finance income		1.3		3.1
Finance expenses		(1.3)		(2.1)
Financial profit / (loss)		(14.8)		(11.3)
Profit / (loss) before income tax		(63.1)		(84.6)
Income tax		(0.9)		9.0
Profit / (loss)		(64.0)		(75.6)
Attributable to:
·   Owners of the parent		(63.9)		(75.5)
·   Non-controlling interests		–		(0.1)
Reported EPS (in €)		(1.66)		(1.96)

Consolidated balance sheet

ASSETS
Other intangible assets		189.2		190.7
Property, plant and equipment		82.9		87.0
Right-of-use assets related to lease contracts		407.2		451.5
Other non-current financial assets		28.9		18.0
Deferred income tax assets		7.2		6.9
Derivative financial instruments		0.3		–
NON-CURRENT ASSETS		715.7		754.1
Inventory		160.5		181.8
Trade receivables and other current receivables		51.2		47.5
Current income tax assets		6.9		7.1
Derivative financial instruments		0.9		–
Cash and cash equivalents		42.4		96.1
CURRENT ASSETS		261.9		332.5
TOTAL ASSETS		977.6		1,086.6
EQUITY AND LIABILITIES
TOTAL EQUITY		23.0		78.1
Non-current borrowings		0.1		25.4
Medium and long-term lease liability		325.8		367.4
Deferred income tax liabilities		16.6		12.2
Post-employment benefits		8.7		9.1
Provisions		17.2		15.3
Derivative financial instruments		–		–
Other non-current liabilities		–
NON-CURRENT LIABILITIES		368.4		429.4
Current borrowings and convertible bonds		257.8		228.1
Short-term lease liability		101.4		106.5
Trade payables and other current payables		222.3		228.8
Provisions		3.6		5,3
Current income tax liabilities		1.1		0.6
Derivative financial instruments		–		9.8
Others current liabilities		–		–
CURRENT LIABILITIES		586.2		579.1
TOTAL LIABILITIES		954.6		1,008.5
TOTAL EQUITY AND LIABILITIES		977.6		1,086.6

Consolidated cash flow statement

(in EUR million – IFRS 16)		H1 2026		H1 2025
Net result		(64.0)		(75.6)
Adjustments for:
·   Depreciation, amortisation, and allowance for provisions		64.3		113.2
·   Net gain/(loss) on disposals		2.8		0.8
·   Fair value – derivative financial instruments		0.6		1.0
·   Change in fair value – unconsolidated investments		–		–
·   Share-based payments		(0.1)		0.1
·   Other		–		–
·   Cost of net financial debt		8.5		5.7
·   Cost of lease debt		6.3		6.6
·   Interest received		(0.2)		–
·   Income Tax		0.9		(9.0)
Change in operating working capital requirement		7.7		(41.0)
Income tax paid		0.9		(0.1)
Net cash generated by/(used in) operating activities(a)		27.8		1.7
Acquisition of non-current assets:
·   Property, plant and equipment		(8.1)		(4.7)
·   Intangible assets		(4.4)		(4.9)
Change in loans and advances granted		(10.8)		0.3
Disposal of financial assets
Change in debts on fixed assets		2.4		(0.7)
Sale of non-current assets		–		1.3
Interest received		0.2		–
Net cash generated by/(used in) investing activities(b)		(20.6)		(8.8)
Impact of changes in scope of consolidation without change of control
Proceeds from issuance of borrowings		0.4		104.2
Repayment of borrowings		(0.9)		(27.6)
Decrease of lease debt		(50.6)		(51.3)
Acquisitions (net) of treasury shares		(0.1)		(0.3)
Dividends paid
Interest paid		(4.0)		(4.5)
Interest on lease debt		(6.4)		(6.5)
Net cash generated by/(used in) financing activities(c)		(61.5)		14.0
Exchange gains/(losses) on cash and cash equivalents		0.3		(1.1)
Net increase/(decrease) in cash & cash equivalents(a)+(b)+(c)		(54.1)		5.8
Cash & cash equivalents at period begin		96.1		90.5
Cash & cash equivalents at period end		42.0		96.3

In addition to the financial indicators set out in International Financial Reporting Standards (IFRS), Maisons du Monde’s management uses several non-IFRS metrics to evaluate, monitor and manage its business. The non- IFRS operational and statistical information related to Group’s operations included in this press release is unaudited and has been taken from internal reporting systems. Although none of these metrics are measures of financial performance under IFRS, the Group believes that they provide important insight into the operations and strength of its business. These metrics may not be comparable to similar terms used by competitors or other companies.

Sales: it includes the revenue from sales of decorative items and furniture through i) Stores (owned or affiliates), ii) to franchisees, iii) websites and iv) B2B activities. They also include marketplace commissions.

Like-for-like sales (LFL) growth: Represents the percentage change in sales from the Group’s retail stores, websites and B2B activities, net of product returns between one financial period (n) and the comparable preceding financial period (n-1), excluding changes in sales attributable to stores that opened or were closed during either of the comparable periods. Sales attributable to stores that closed temporarily for refurbishment during any of the periods are included. 

Gross margin: Is defined as sales minus cost of sales. Gross margin is also expressed as a percentage of Sales. 

Current EBITDA: Is defined as current operating profit, excluding: 

1. i. depreciation, amortization, and allowance for provisions and, 
2. ii. the change in the fair value of derivative financial instruments. The EBITDA margin is calculated as EBITDA divided by Sales. 

LTM EBITDA: Last twelve months EBITDA before IFRS 16

Current EBIT: Is defined as current EBITDA minus depreciation, amortization, and allowance for provisions. The EBIT margin is calculated as EBIT divided by Sales. 

Net debt (without IFRS 16) : Is defined as the Group’s finance leases, unsecured term loan, unsecured revolving credit facilities, deposits and bank borrowings, net of cash and cash equivalents. 

Free cash flow: Is defined as net cash from operating activities less the sum of capital expenditures (capital outlays for property, plant and equipment, intangible, other non-current assets, change in debt on fixed assets, proceeds from disposal of non-current assets and financial) and reduction of rental debt and interest on rental debt.

Disclaimer: Forward Looking Statement

This press release contains certain statements that constitute “forward-looking statements,” including but not limited to statements that are predictions of or indicate future events, trends, plans or objectives, based on certain assumptions or which do not directly relate to historical or current facts. Such forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the future results expressed, forecasted or implied by such forward- looking statements. Accordingly, no representation is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Any forward-looking statements included in this press release speak only as of the date hereof and will not give rise to updates or revision. For a more complete list and description of such risks and uncertainties, refer to Maisons du Monde’s filings with the French Autorité des marchés financiers.

Financial agenda

The below financial calendar is provided for indicative purposes only and may be subject to change, please refer to our Corporate Web Site

22 October 2026 Q3 and 9-month 2026 Sales

About Maisons du Monde

Maisons du Monde is the leading player in inspiring, accessible, and sustainable home and decoration. The Brand offers a rich and constantly refreshed range of furniture and decorative items in a multitude of styles. Leveraging a highly efficient omnichannel model and direct access to consumers, the Group generates over 50% of its sales through its online platform and operates in 8 European countries.

corporate.maisonsdumonde.com

Contacts

Investor Relations	Press Relations
Denis Lamoureux Tel: (+33) 6 46 35 09 95	Pierre Barbe Tel: (+33) 6 23 23 08 51
dlamoureux@maisonsdumonde.com	pbarbe@maisonsdumonde.com Michelle Kamar Tel : (+33) 6 09 24 42 42 michelle@source-rp.com

Attachment

• Press release – Maisons du Monde I H1 26 Financial results

Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic activity

HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity. The findings are being presented at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, held September 25–28, 2026 in San Diego, California.

In preclinical models of pancreatic cancer, Annamycin’s antitumor activity appears to depend in part on CD8+ T cells, the immune system’s primary tumor-killing cells. The finding suggests Annamycin may do more than kill cancer cells directly; it may also expose tumors that are typically considered immunologically “cold” to immune attack.

Pancreatic cancer is among the most treatment-resistant solid tumors, and its characteristically “cold” immune microenvironment is one reason checkpoint inhibitors have shown limited single-agent activity in the disease. Preclinical evidence that Annamycin’s activity is partly immune-mediated points to a potential basis for combination approaches, and complements the immune-modulating mechanism of the Company’s WP1066 program.

Title: “Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity”
Author/Presenter: Angela T. Alistar, MD, Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center
Congress: AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
Dates: September 25–28, 2026
Location: Hilton San Diego Bayfront, San Diego, California

These findings were generated in preclinical models. Preclinical results may not be predictive of results in humans, and Annamycin is not currently in clinical development for the treatment of pancreatic cancer.

The abstract for this presentation was published today as a supplement to the September 15, 2026 issue of Cancer Research.

“Annamycin represents a fundamental re-engineering of the anthracycline, one designed to increase efficacy and avoid multidrug resistance and the cardiotoxicity of currently prescribed agents,” said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. “These data point to an unexpected additional benefit. In preclinical models of pancreatic cancer, Annamycin’s antitumor activity appears to depend in part on the immune system. If that observation holds, it broadens both where Annamycin might be useful and how it might be combined.”

Annamycin’s lead clinical program remains the ongoing MIRACLE trial evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia (AML), which is the Company’s primary development focus and the basis of its near-term milestones. The pancreatic cancer findings described above are preclinical and are not part of the MIRACLE trial.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

• SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model – 
• Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy –
• SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009 activity against MYC-driven pancreatic cancer biology –

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies evaluating SLS009 (tambiciclib), its highly selective cyclin-dependent kinases 9 (CDK9) inhibitor, in patient-derived organoid models of pancreatic ductal adenocarcinoma (PDAC). The data are being presented at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, being held September 25–28, 2026, in San Diego. The timing of this announcement reflects AACR’s embargo policy, under which the data presented at the conference were restricted from publication until 1:00 p.m. ET today.

The studies, conducted in collaboration with researchers at the University of Wisconsin–Madison, evaluated SLS009 in MYC-amplified PDAC models, including a model resistant to the recently approved RAS inhibitor daraxonrasib (RMC-6236), as well as in combination with the BET inhibitor ZEN3694. MYC amplification is a biologically recognized mechanism of RAS targeting resistance.

“These findings provide encouraging preclinical evidence that CDK9 inhibition may enhance the activity of RAS-directed therapy in pancreatic cancer, including in the setting of MYC-associated resistance,” said Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. “In a daraxonrasib-resistant patient-derived model, SLS009 demonstrated substantially greater activity than daraxonrasib alone and further increased apoptosis and necrosis when the two agents were combined. Together with the synergistic activity observed with BET inhibition, these data support a broader strategy of using SLS009 to disrupt transcriptional programs that may contribute to resistance to RAS-targeted therapies and provide a strong rationale for further evaluation in pancreatic cancer patients.”

In a MYC-amplified, daraxonrasib-resistant patient-derived PDAC organoid model, SLS009 at 200 nM, daraxonrasib at 100 nM, and the combination of both agents were evaluated. Daraxonrasib was administered continuously, while SLS009 was removed after 24 hours to approximate its in vivo pharmacokinetic profile, with apoptosis and necrosis assessed at 72 hours.

A separate MYC-amplified patient-derived PDAC organoid model evaluated SLS009 in combination with the BET inhibitor ZEN3694. The combination demonstrated synergistic activity, including increased cancer cell death and sustained suppression of MYC transcription. Notably, these effects were observed at a ZEN3694 concentration substantially below reported physiologically achievable exposure levels.

Key findings:

• SLS009 demonstrated substantially greater single-agent activity than daraxonrasib in the daraxonrasib-resistant model, inducing 17.9% apoptosis versus 2.8% with daraxonrasib and 14.5% necrosis versus 2.7%.
• The combination of SLS009 and daraxonrasib further increased cancer cell death, inducing 36.5% apoptosis and 30.6% necrosis, compared with 17.9% and 14.5%, respectively, with SLS009 alone and 2.8% and 2.7%, respectively, with daraxonrasib monotherapy.
• SLS009 combined with ZEN3694 demonstrated synergistic activity, producing greater apoptosis and necrosis than either agent alone.
• The SLS009/ZEN3694 combination produced sustained suppression of MYC RNA and reduced expression of MYC and MCL-1 proteins, consistent with disruption of transcriptional pathways supporting tumor cell survival.

Together, the findings support further investigation of CDK9 inhibition as a strategy to enhance RAS-directed therapy and potentially address MYC-associated resistance in pancreatic cancer. The BET combination data provide additional mechanistic support for SLS009-based approaches designed to disrupt MYC-dependent transcriptional programs and suggest the potential to enhance BET inhibition at lower drug exposures.

“MYC is a particularly challenging oncogenic driver because it has historically been difficult to target directly,” said Jeremy D. Kratz, MD, Assistant Professor of Medicine and Principal Investigator at the University of Wisconsin–Madison. “Across these studies, CDK9 inhibition produced substantial activity in MYC-amplified pancreatic cancer models through two distinct therapeutic strategies. The activity of SLS009 supports its activity in a model with de novo daraxonrasib-resistance and together with the synergistic transcriptional suppression observed with BET inhibition, provides a strong rationale for further investigation of SLS009-based combinations in molecularly defined subsets of pancreatic cancer.”

Poster presentation details:

Title: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids
Authors: Sawyer AG, Flannagan LE, Esguerra PN, Hossan MS, Kratz JD
Poster Number: A036 – September 27, 2026: 5-7pm PST

Title: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma
Authors: Esguerra PN, Cadarso M, Livingwell S, Hossan MD, Wong O, Kratz JD
Poster Number: B127 – September 27, 2026: 5-7pm PST

Title: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma
Authors: Cadarso M, Esguerra P, Flannagan L, Hossan MS, Kratz JD
Poster Number: B043 – September 27, 2026: 5-7pm PST

The posters will be available on SELLAS’ website following the conference.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) – potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact

Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
jbosisio@simpsonhealthcare.com

FAIRFAX, Va., Sept. 25, 2026 (GLOBE NEWSWIRE) — WidePoint Corporation (NYSE American: WYY), a leading provider of Secure Mobile Management and Managed Services Solutions, today provided an update regarding the Government Accountability Office (GAO) decision concerning the Department of Homeland Security (DHS) Cellular Wireless Managed Services (CWMS) 3.0 contract. The GAO has notified WidePoint that it has sustained the protest filed by TurningPoint Global Solutions regarding the award. It is important to note that a “sustained” protest does not necessarily conclude the procurement process; rather, it is a routine mechanism within federal contracting that may lead to various outcomes, including corrective actions or re-evaluations, as determined by the agency.

In accordance with standard federal procurement procedures and the protective order currently in place, the specific findings and recommendations of the GAO decision remain under seal and are not publicly available at this time. The attorneys for the parties are in the process of reviewing the protected decision for potential redactions of sensitive information before a public version of the decision is issued. As a result, the full details of the decision are not yet available to WidePoint or the public.

WidePoint is committed to a transparent and thorough process. Once the public decision is issued, the company will work with legal counsel to review the GAO decision and WidePoint’s options in response to it, and WidePoint is engaging with DHS to understand the agency’s next steps in response to the decision.

WidePoint continues to maintain a strong, productive relationship with DHS and remains fully focused on delivering exceptional service and value to all of our federal and commercial clients. Further updates will be provided as appropriate and in accordance with regulatory requirements.

About WidePoint
WidePoint Corporation (NYSE American: WYY) is a leading technology Managed Solution Provider (MSP) dedicated to securing and protecting the mobile workforce and enterprise landscape. WidePoint is recognized for pioneering technology solutions that include Identity & Access Management (IAM), Mobility Managed Services (MMS), Telecom Management, Information Technology as a Service, Cloud Security, and Analytics & Billing as a Service (ABaaS). To learn more, visit https://www.widepoint.com. 

WidePoint Investor Relations:
Gateway Group, Inc.
Matt Glover or John Yi
949-574-3860
WYY@gateway-grp.com

Orion Corporation: Acquisition of own shares during week 39, 2026

The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.

Orion Corporation’s shares have been acquired as follows:

Date	Exchange transaction		Share trading code	Number of shares		Average price/ share (EUR)*	Total transaction value (EUR)
September 21, 2026	Buy	ORNBV		23,704	82.2724			1,950,184.97
September 22, 2026	Buy	ORNBV		22,639	83.2528			1,884,760.14
September 23, 2026	Buy	ORNBV		23,552	83.3016			1,961,919.28
September 24, 2026	Buy	ORNBV		23,842	82.5790			1,968,848.52
September 25, 2026	Buy	ORNBV		20,000	83.0657			1,661,314.00
Total during week 39/2026	Buy	ORNBV		113,737	82.8844			9,427,023.00

*Average price rounded to four decimal places

After these acquisitions, Orion Corporation holds a total of 730,383 treasury shares which all are Class B shares.

On behalf of Orion Corporation

Danske Bank A/S, Finland Branch
Antti Väliaho, Jonathan Nyberg

For more information, please contact:

Tuukka Hirvonen, Head of Investor Relations
Orion Corporation
Tel. +358 10 426 2721, tuukka.hirvonen@orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

Attachment

• FI0009014377_20260925